Id: | acc4661 |
Group: | 1sens |
Protein: | eIF2alpha |
Gene Symbol: | Eif2a |
Protein Id: | Q8BJW6 |
Protein Name: | EIF2A_MOUSE |
PTM: | phosphorylation |
Site: | Ser51 |
Site Sequence: | YTFSKDGTLFAWSNGEKVNII |
Disease Category: | Infectious diseases |
Disease: | Prion Diseases |
Disease Subtype: | |
Disease Cellline: | N2a |
Disease Info: | |
Drug: | Sephin1 |
Drug Info: | Sephin1 is a drug that may have specific therapeutic effects and is used in relevant medical research or treatment. |
Effect: | modulate |
Effect Info: | "Sephin1 alleviates endoplasmic reticulum (ER) stress, reduces the expression of abnormal PrP proteins, and prolongs the survival time of prion-infected mice by prolonging the phosphorylation of eIF2α." |
Note: | |
Score: | 4.0 |
Pubmed(PMID): | 31981074 |
Sentence Index: | 31981074_4 |
Sentence: | "Here, we describe the anti-prion effect of the chemical compound Sephin1 which has been shown to protect in mouse models of protein misfolding diseases including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS) by selectively inhibiting the stress-induced regulatory subunit of protein phosphatase 1, thus prolonging eIF2alpha phosphorylation." |
Sequence & Structure:
MAPSTPLLTVRGSEGLYMVNGPPHFTESTVLPRESGRNCKVYTFSKDGTLFAWSNGEKVNIINVANKGLLHSFDLPKAVCLEFSPNNTVLATWQPYTTSKDGTAGTPNLQLYDMKTGACLKSFIQKKMQNWCPSWSDDEIICARNVNNEVHFFENNNFNTIANKLHLQKVNDFNLSPGTQPYKVAVYVPGSKGAPSFVRLYQYPNFAGPQAALANKSFFKADKVTMLWNKKATAVLVIASTEVDKTGASYYGEQTLHYIATNGESAVVQLPKNGPIYDVVWNSSSTEFCAVYGFMPAKATVFNLKCDPVFDFGTGPRNAAFYSPHGHILVLAGFGNLRGQMEVWDVKNYKLISKPVASDSTYFAWCPDGEHILTATCAPRLRVNNGYKIWHYTGSLLHKYDVPSNGELWQVSWQPFLDGIFPAKTIKYQAVPSEVPSEEPKVATAYRPPALRNKPVTNSKLHEEEPPQNMKPHPGSDKPLSKTALKNQRKHEAKKAAKQEARSDAAPTPVPQSAPRNTVTQSASGDPEVDKKIKNLKKKLKAIEQLKEQAAAGKQLEKNQLEKIQKETALLQELEDLELGV
No data.
No data.
Protein Tractability:
source: Open TargetsNo data.
PTM Intensity:
source: CPTACNo data.
PTM-Disease Association:
source: PTMDNo data.
PTM-Drug Perturbation Response:
source: DecryptMNo data.
Function score:
source: funscoRNo data.